Announced
Financials
Tags
Public
Friendly
Single Bidder
Merger
Tender Offer
specialty pharmaceuticals
United States
Pharmaceuticals
Majority
Failed
Synopsis
Melinta Therapeutics, an American biopharmaceutical firm, terminated the $57m acquisition of Tetraphase Pharmaceuticals, a biopharmaceutical company. “This transaction increases our world-class infectious disease portfolio and we are eager to build upon our synergies and leverage our collective expertise and scale to offer patients and providers battling serious bacterial infections with an additional potentially life-saving treatment option,” Jennifer Sanfilippo, Melinta Interim CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.